| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on January 27, 2009
From the Department of Neurology (N.A., N.W.), Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; the Department of Clinical Neurosciences (M.B.), Danube University, Krems, Austria; the Department of Neurology (J.C.), Hospital Clínico Universitario–University of Santiago de Compostela, Santiago de Compostela, Spain; Newcastle Acute Stroke Unit (G.A.F.), Institute for Ageing and Health, Newcastle University, UK; the Department of Neurology (M.K.), Helsinki University Central Hospital, Helsinki, Finland; the Acute Stroke Unit and Cerebrovascular Clinic (K.R.L.), Division of Cardiovascular and Medical Sciences, Western Infirmary, Faculty of Medicine, University of Glasgow, Glasgow, UK; and the Emergency Department Stroke Unit (D.T.), La Sapienza University, Policlinico Umberto I, Rome, Italy. * To whom correspondence should be addressed. E-mail: niaz.ahmed{at}karolinska.se.
Background and Purpose—The optimal management of blood pressure (BP) in acute stroke remains unclear. For ischemic stroke treated with intravenous thrombolysis, current guidelines suggest pharmacological intervention if systolic BP exceeds 180 mm Hg. We determined retrospectively the association of BP and antihypertensive therapy with clinical outcomes after stroke thrombolysis. Methods—The SITS thrombolysis register prospectively recorded 11 080 treatments from 2002 to 2006. BP values were recorded at baseline, 2 hours, and 24 hours after thrombolysis. Outcomes were symptomatic (National Institutes of Health Stroke Scale score deterioration Results—In multivariable analysis, high systolic BP 2 to 24 hours after thrombolysis as a continuous variable was associated with worse outcome (P<0.001) and as a categorical variable had a linear association with symptomatic hemorrhage and a U-shaped association with mortality and independence with systolic BP 141 to 150 mm Hg associated with most favorable outcomes. OR (95% CI) from multivariable analysis showed no difference in symptomatic hemorrhage (1.09 [0.83 to 1.51]; P=0.58) and independence (1.03 [0.93 to 1.10]; P=0.80) but lower mortality (0.82 [0.73 to 0.92]; P=0.0007) for Group 1 compared with Group 4. Group 2 had a higher symptomatic hemorrhage (1.86 [1.34 to 2.68]; P=0.0004) and mortality (1.62 [1.41 to 1.85]; P<0.0001) and lower independence (0.89 [0.80 to 0.99]; P=0.04) compared with Group 4. Group 3 had similar results as Group 1. Conclusions—There is a strong association of high systolic BP after thrombolysis with poor outcome. Withholding antihypertensive therapy up to 7 days in patients with a history of hypertension was associated with worse outcome, whereas initiation of antihypertensive therapy in newly recognized moderate hypertension was associated with a favorable outcome.
Accepted on March 5, 2009
Relationship of Blood Pressure, Antihypertensive Therapy, and Outcome in Ischemic Stroke Treated With Intravenous Thrombolysis. Retrospective Analysis From Safe Implementation of Thrombolysis in Stroke–International Stroke Thrombolysis Register (SITS-ISTR)
Niaz Ahmed MD, PhD*;
4) intracerebral hemorrhage Type 2, mortality, and independence at (modified Rankin Score 0 to 2) 3 months. Patients were categorized by history of hypertension and antihypertensive therapy within 7 days after thrombolysis: Group 1, hypertensive treated with antihypertensives (n=5612); Group 2, hypertensive withholding antihypertensives (n=1573); Group 3, without history of hypertension treated with antihypertensives (n=995); and Group 4, without history of hypertension not treated with antihypertensives (n=2632). For 268 (2.4%) patients, these data were missing. Average systolic BP 2 to 24 hours after thrombolysis was categorized by 10-mm Hg intervals with 100 to 140 used as a reference.
This article has been cited by other articles:
![]() |
K. Toyoda, M. Koga, M. Naganuma, Y. Shiokawa, J. Nakagawara, E. Furui, K. Kimura, H. Yamagami, Y. Okada, Y. Hasegawa, et al. Routine Use of Intravenous Low-Dose Recombinant Tissue Plasminogen Activator in Japanese Patients: General Outcomes and Prognostic Factors From the SAMURAI Register Stroke, November 1, 2009; 40(11): 3591 - 3595. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Tsivgoulis, J. L. Frey, M. Flaster, V. K. Sharma, A. Y. Lao, S. L. Hoover, W. Liu, E. Stamboulis, A. W. Alexandrov, M. D. Malkoff, et al. Pre-Tissue Plasminogen Activator Blood Pressure Levels and Risk of Symptomatic Intracerebral Hemorrhage Stroke, November 1, 2009; 40(11): 3631 - 3634. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Leira, M. Millan, E. Diez-Tejedor, M. Blanco, J. Serena, B. Fuentes, M. Rodriguez-Yanez, M. Castellanos, A. Lago, A. Davalos, et al. Age Determines the Effects of Blood Pressure Lowering During the Acute Phase of Ischemic Stroke: The TICA Study Hypertension, October 1, 2009; 54(4): 769 - 774. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |